CCL13 and atopic eczema: In 2018, the FDA authorized the oral medication ASN002, a dual JAK/SYK inhibitor, for the treatment of moderate to severe atopic dermatitis; ASN002 significantly reverses the transcriptome of lesional skin to a nonlesional phenotype and inhibits key inflammatory pathways involved in the pathogenesis of AD, including CCL13-mediated Th2-associated inflammation (18).